Literature DB >> 8119050

Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction. Population analysis of a randomised concentration controlled trial.

N Holford1, Y Hashimoto, L B Sheiner.   

Abstract

Peak expiratory flow rate, adverse effects and serum theophylline concentration were measured during treatment of episodes of severe airways obstruction. 174 patients were randomised to target theophylline concentrations of 10 mg/L or 20 mg/L. The recovery of peak flow rate towards normal values was explicable in terms of time and theophylline concentration using semiparametric and parametric nonlinear regression models. In the absence of theophylline, recovery takes place with a half-time of 16 hours. Theophylline is less effective in achieving recovery than the passage of time but achieves 50% of possible recovery at a concentration of 11 mg/L. The action of theophylline is most marked at the start of treatment. It may no longer have important beneficial effects after 72 hours. The incidence of adverse effects increased at theophylline concentrations > 20 mg/L.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8119050     DOI: 10.2165/00003088-199325060-00008

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  9 in total

1.  Nonlinear mixed effects models for repeated measures data.

Authors:  M L Lindstrom; D M Bates
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

2.  Pulmonary function in the elderly: response to theophylline bronchodilation.

Authors:  M H Chandler; G D Clifton; N K Burki; B A Hunt; R A Blouin
Journal:  J Clin Pharmacol       Date:  1990-04       Impact factor: 3.126

3.  A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease.

Authors:  D Murciano; M H Auclair; R Pariente; M Aubier
Journal:  N Engl J Med       Date:  1989-06-08       Impact factor: 91.245

4.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

Review 5.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

6.  Aminophylline increases the toxicity but not the efficacy of an inhaled beta-adrenergic agonist in the treatment of acute exacerbations of asthma.

Authors:  D Siegel; D Sheppard; A Gelb; P F Weinberg
Journal:  Am Rev Respir Dis       Date:  1985-08

7.  Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline.

Authors:  S Vozeh; G Kewitz; A Perruchoud; M Tschan; C Kopp; M Heitz; F Follath
Journal:  Am Rev Respir Dis       Date:  1982-02

8.  Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? A randomised concentration-controlled trial.

Authors:  N Holford; P Black; R Couch; J Kennedy; R Briant
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

9.  Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction.

Authors:  B M Frey; F J Frey; N H Holford; F Lozada; L Z Benet
Journal:  Transplantation       Date:  1982-06       Impact factor: 4.939

  9 in total
  15 in total

1.  Target concentration intervention: beyond Y2K.

Authors:  N H Holford
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 2.  Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials?

Authors:  A Grahnén; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.

Authors:  Andrew Hooker; Paolo Vicini
Journal:  AAPS J       Date:  2005-11-01       Impact factor: 4.009

4.  Randomized exposure-controlled trials; impact of randomization and analysis strategies.

Authors:  Kristin E Karlsson; Anders Grahnén; Mats O Karlsson; E Niclas Jonsson
Journal:  Br J Clin Pharmacol       Date:  2007-04-10       Impact factor: 4.335

Review 5.  Clinical pharmacology = disease progression + drug action.

Authors:  Nick Holford
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

Review 6.  Expanding clinical applications of population pharmacodynamic modelling.

Authors:  C Minto; T Schnider
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 7.  The target concentration approach to clinical drug development.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

8.  Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.

Authors:  B Royer; W Yin; M Pegram; N Ibrahim; C Villanueva; D Mir; F Erlandsson; X Pivot
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

9.  Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment.

Authors:  Bernard Royer; Vincent Jullien; Emmanuel Guardiola; Bruno Heyd; Bruno Chauffert; Jean-Pierre Kantelip; Xavier Pivot
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials.

Authors:  R Graham Barr; Brian H Rowe; Carlos A Camargo
Journal:  BMJ       Date:  2003-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.